Real study: Re-treatment evaluated on visual acuity for Lucentis ® in neovascular AMD.

CONCLUSION: This initial VA-guided regimen with ranibizumab might prevent the slight decrease in VA observed during the first year of PRN studies. PMID: 29779934 [PubMed - as supplied by publisher]
Source: Journal Francais d Ophtalmologie - Category: Opthalmology Tags: J Fr Ophtalmol Source Type: research